Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium
NCT03761901 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 141
Last updated 2020-05-08
Summary
This is a retrospective, observational, multicentre study to evaluate treatment patterns and outcomes of patients diagnosed with locally advanced or metastatic EGFRm NSCLC in Belgium
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
- DRUG
-
1L treatment
chemotherapy, EGFR TKI, immunotherapy, other
- DRUG
-
2L Treatment
Chemotherapy, EGFR TKI, immunotherapy, other
- DRUG
-
3L treatment
chemotherapy, EGFR TKI, immunotherapy, other
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-09-21
- Primary Completion
- 2019-06-19
- Completion
- 2019-06-19
Countries
- Belgium
Study Locations
More Related Trials
-
Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR)
NCT02293733 ·Status: COMPLETED
-
Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients
NCT01717105 ·Status: UNKNOWN
-
An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation
NCT03810872 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
NCT01260181 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex
NCT02876081 ·Status: WITHDRAWN ·Phase: PHASE2
-
Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma
NCT01167972 ·Status: COMPLETED
-
A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.
NCT01250119 ·Status: COMPLETED ·Phase: PHASE2
-
Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)
NCT01931306 ·Status: APPROVED_FOR_MARKETING
-
Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer
NCT02716311 ·Status: COMPLETED ·Phase: PHASE2
-
Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer
NCT03727724 ·Status: COMPLETED ·Phase: PHASE2
-
Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
NCT01081496 ·Status: COMPLETED
-
LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib
NCT04216121 ·Status: RECRUITING
-
GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations
NCT02047903 ·Status: COMPLETED
-
Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.
NCT01525199 ·Status: COMPLETED
-
A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR
NCT02178397 ·Status: TERMINATED ·Phase: PHASE3
-
The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib
NCT04640870 ·Status: COMPLETED
-
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
NCT02134015 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT01667562 ·Status: COMPLETED ·Phase: PHASE3
-
Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed.
NCT04737382 ·Status: RECRUITING ·Phase: NA
-
D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer
NCT03861156 ·Status: COMPLETED ·Phase: PHASE2
-
Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC
NCT02064491 ·Status: COMPLETED ·Phase: PHASE2
-
Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer
NCT04742192 ·Status: COMPLETED
-
Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas
NCT01380795 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
NCT04324164 ·Status: RECRUITING
-
EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations
NCT03516214 ·Status: COMPLETED ·Phase: PHASE1